Brockmueller Aranka, Mueller Anna-Lena, Kunnumakkara Ajaikumar B, Aggarwal Bharat B, Shakibaei Mehdi
Musculoskeletal Research Group and Tumor Biology, Chair of Vegetative Anatomy, Faculty of Medicine, Institute of Anatomy, Ludwig-Maximilians-University Munich, Munich, Germany.
Cancer Biology Laboratory and DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Department of Biosciences and Bioengineering, Indian Institute of Technology (IIT) Guwahati, Guwahati, India.
Front Oncol. 2022 Sep 16;12:962066. doi: 10.3389/fonc.2022.962066. eCollection 2022.
Chronic diseases including cancer have high case numbers as well as mortality rates. The efficient treatment of chronic diseases is a major ongoing medical challenge worldwide, because of their complexity and many inflammatory pathways such as JNK, p38/MAPK, MEK/ERK, JAK/STAT3, PI3K and NF-κB among others being implicated in their pathogenesis. Together with the versatility of chronic disease classical mono-target therapies are often insufficient. Therefore, the anti-inflammatory as well as anti-cancer capacities of polyphenols are currently investigated to complement and improve the effect of classical anti-inflammatory drugs, chemotherapeutic agents or to overcome drug resistance of cancer cells. Currently, research on Calebin A, a polyphenolic component of turmeric (), is becoming of growing interest with regard to novel treatment strategies and has already been shown health-promoting as well as anti-tumor properties, including anti-oxidative and anti-inflammatory effects, in diverse cancer cells. Within this review, we describe already known anti-inflammatory activities of Calebin A modulation of NF-κB and its associated signaling pathways, linked with TNF-α, TNF-β and COX-2 and further summarize Calebin A's tumor-inhibiting properties that are known up to date such as reduction of cancer cell viability, proliferation as well as metastasis. We also shed light on possible future prospects of Calebin A as an anti-cancer agent.
包括癌症在内的慢性疾病具有较高的病例数和死亡率。由于慢性疾病的复杂性以及许多炎症信号通路（如JNK、p38/MAPK、MEK/ERK、JAK/STAT3、PI3K和NF-κB等）参与其发病机制，因此有效治疗慢性疾病是全球范围内一项持续存在的重大医学挑战。鉴于慢性疾病的多样性，经典的单一靶点疗法往往并不充分。因此，目前正在研究多酚类物质的抗炎和抗癌能力，以补充和提高经典抗炎药物、化疗药物的疗效，或克服癌细胞的耐药性。目前，姜黄中的多酚成分calebin A在新型治疗策略方面的研究越来越受到关注，并且已经在多种癌细胞中显示出促进健康以及抗肿瘤特性，包括抗氧化和抗炎作用。在这篇综述中，我们描述了calebin A已知的抗炎活性——对NF-κB及其相关信号通路的调节，这些通路与TNF-α、TNF-β和COX-2相关，并进一步总结了calebin A迄今为止已知的肿瘤抑制特性，如降低癌细胞活力、增殖以及转移能力。我们还阐述了calebin A作为抗癌药物可能的未来前景。
